ORIC Pharmaceuticals, Inc. develops clinical-stage oncology therapies designed to counter mechanisms of therapeutic resistance in cancer. News about ORIC commonly covers rinzimetostat (ORIC-944), a selective allosteric PRC2/EED inhibitor studied in prostate cancer and metastatic castration-resistant prostate cancer, and enozertinib (ORIC-114), a brain-penetrant selective inhibitor targeting EGFR exon 20 insertion mutations and EGFR atypical mutations.
Recurring updates include clinical and preclinical data presentations, development-dose decisions, oncology conference presentations, quarterly financial results, cash runway disclosures, at-the-market equity financing, and Nasdaq Rule 5635(c)(4) inducement equity grants.
ORIC Pharmaceuticals (ORIC) initiated its Himalayas-1 Phase 3 prostate cancer trial and reported a wider third-quarter net loss. Net loss was $48.076 million, versus $32.587 million a year earlier. Cash and investments totaled $345.4 million at September 30, 2026; ORIC expects funding into the second half of 2028.
Preliminary rinzimetostat combination results showed 59% estimated freedom from radiographic progression at 10 months in both previously treated prostate cancer cohorts. Bayer will supply darolutamide free for Himalayas-1, while ORIC retains global rinzimetostat rights. Enozertinib produced investigator-confirmed response rates of 84% systemically and 70% intracranially in first-line EGFR atypical lung cancer. ORIC plans to start its Redwood-1 Phase 3 trial in the first half of 2027. Cancer Research UK will fund and conduct early development of ORIC-259, with ORIC retaining an option to reacquire rights.
ORIC Pharmaceuticals (Nasdaq: ORIC) granted equity awards to one new non-executive employee on November 2, 2026, as an inducement to employment.
The awards comprise 14,800 non-qualified stock options and 2,400 restricted stock units under its 2022 Inducement Equity Incentive Plan. The options have an exercise price equal to the stock’s closing price on the grant date. Options vest 25% after one year, with one thirty-sixth of the remaining shares vesting monthly thereafter. Restricted stock units vest one-third on each of the first three grant-date anniversaries. Vesting requires continued employment or service.
ORIC Pharmaceuticals (Nasdaq: ORIC) announced management will participate in three investor conferences in November 2026, with fireside chats and one-on-one meetings.
Chats are scheduled for Guggenheim on November 10 at 10:30 a.m. ET, Stifel on November 11 at 2:00 p.m. ET, and Jefferies London on November 18 at 12:30 p.m. GMT. Webcasts will be available on the investor website, with replays available for 90 days following each event.
ORIC Pharmaceuticals (ORIC) reported enozertinib Phase 1b lung cancer results and plans to advance the drug into a global Phase 3 trial. Among previously untreated patients with EGFR atypical mutations, confirmed systemic objective response rates (tumor shrinkage) were 84% by investigators and 80% by blinded independent review. The September 4, 2026 dataset included 26 patients; 65% had baseline brain metastases.
Intracranial response rates were 70% by investigators and 67% under independent RANO-BM brain-metastasis criteria. Six-month progression-free survival was 88%, but median survival without progression and response duration remain immature. Grade 3 treatment-related adverse events affected 23%; none caused treatment discontinuation. ORIC expects to initiate Redwood-1 in the first half of 2027, enrolling approximately 360 patients and comparing enozertinib with physician’s choice of osimertinib or afatinib.
ORIC Pharmaceuticals (ORIC) presented preclinical and patient-sample data at ESMO Congress 2026 supporting rinzimetostat’s potential to enhance androgen receptor inhibition in prostate cancer. In preclinical studies, rinzimetostat maintained potency against an EZH2 mutation associated with resistance to mevrometostat; no rinzimetostat-resistant cells emerged. No hematologic tumorigenesis was observed in its rat toxicology study, versus tumorigenesis demonstrated with tazemetostat.
Rinzimetostat reinforced dependence on the androgen receptor (AR), restricted changes in cell identity and synergized with AR inhibition in preclinical models. In samples from patients with metastatic castration-resistant prostate cancer, most assessed showed shifts indicating increased AR signaling after one treatment cycle; paired biopsies showed increased PSMA and KLK2 markers. ORIC said the findings support further evaluation, including in the ongoing Himalayas-1 Phase 3 trial.
ORIC Pharmaceuticals (Nasdaq: ORIC) will host a conference call and webcast on October 23, 2026, to review enozertinib clinical data.
The call begins at 8:00 a.m. ET and covers the ongoing Phase 1b trial in previously untreated patients with non-small cell lung cancer (NSCLC) carrying atypical EGFR mutations. ORIC plans to have Dr. Joshua Sabari join the discussion. The data will be presented in conjunction with ESMO Congress 2026 in Madrid, October 23–27. Three posters cover enozertinib and rinzimetostat; abstracts are publicly available, and posters will be available on October 23.
ORIC Pharmaceuticals (Nasdaq: ORIC) has agreed with Cancer Research UK to advance its CIP2A-targeted cancer therapy ORIC-259 into clinical development. Cancer Research UK’s Centre for Drug Development will fully fund, sponsor, design and execute studies needed for a clinical trial application and Phase 1/2 development in patients with cancer.
ORIC retains an exclusive option to reacquire rights to ORIC-259 following Phase 1/2 data. Cancer Research UK is eligible for downstream milestone payments and royalties. ORIC-259 is a small molecule designed to degrade messenger RNA, the instructions used to make the CIP2A protein. ORIC describes preclinical antitumor activity in settings sensitive and resistant to PARP inhibitors, supporting planned clinical development for cancers with homologous recombination deficiency, a defect in DNA repair.
ORIC Pharmaceuticals (ORIC) granted equity awards to six new non-executive employees on October 1, 2026, as an inducement to employment.
The awards comprise 161,550 non-qualified stock options and 26,850 restricted stock units under the 2022 Inducement Equity Incentive Plan. The employees joined in September 2026. Options have an exercise price equal to the common stock's closing price on the grant date. Options vest 25% after one year, with one thirty-sixth of the remaining shares vesting each month thereafter. Restricted stock units vest one-third on each of the first three grant-date anniversaries. Vesting requires continued employment or service. The board's Compensation Committee approved the grants under Nasdaq Listing Rule 5635(c)(4).
ORIC Pharmaceuticals (ORIC) granted inducement equity awards to two new non-executive employees effective September 1, 2026. The awards comprise 39,200 non-qualified stock options and 6,400 restricted stock units issued under the 2022 Inducement Equity Incentive Plan, subject to continued employment or service. The stock options have an exercise price equal to the closing price of ORIC’s common stock on the grant date. Options vest 25% after one year, then 1/36 of the remainder monthly, while RSUs vest in three equal annual installments. The Compensation Committee approved the grants as material inducements to employment in line with Nasdaq Rule 5635(c)(4).
ORIC Pharmaceuticals (ORIC) will participate in three healthcare investor conferences in September 2026, featuring management fireside chats and one-on-one meetings.
Events include the Wells Fargo 21st Annual Healthcare Conference on September 9 at 2:15 p.m. ET, the Cantor Global Healthcare Conference on September 10 at 1:35 p.m. ET, and the Morgan Stanley 24th Annual Global Healthcare Conference on September 15 at 10:00 a.m. ET. Live webcasts and 90-day replays will be accessible via the investor section of the company website.